Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339309 | 0.81 | CYP1A2 (0.37) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3236730 | 0.81 | CYP1A2 (0.37) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8430039 | 0.79 | CYP1A2 (0.36) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL15385471 | 0.79 | MAPK1 (0.33) | — | |
| SCHEMBL3399318 | 0.79 | CYP1A2 (0.36) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL12499925 | 0.77 | MAPK1 (0.31) | CYP1A2HIF1A | |
| SCHEMBL4128790 | 0.76 | CYP1A2 (0.36) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3813382 | 0.76 | KDM4E (0.37) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29328848 | 0.75 | CYP1A2 (0.38) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL22309984 | 0.75 | CYP1A2 (0.35) | CYP1A2HIF1AALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2009123967-A1 | 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | CYP1A2 1655/4885HIF1A 1898/4885ALDH1A1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.